XOMA announces two new BPI patents.BERKELEY, Calif.--(BUSINESS WIRE)--Aug. 2, 1995--XOMA Corporation (Nasdaq:XOMA) today announced that the U.S. Patent Office will issue two patents related to the company's Bactericidal/Permeability-Increasing Protein (BPI (Bits Per Inch) The measurement of the number of bits stored in one linear inch of a track (storage channel) on a disk or tape. Bit density on magnetic disks has reached 800,000 bpi (800 Kbpi). See tpi, areal density and magnetic disk. BPI - bits per inch ) products. The new patents represent XOMA's first BPI manufacturing process-related patent and second BPI product patent. The process-related patent describes a preferred method of producing recombinant BPI proteins, including XOMA's lead product, Neuprex(TM) (rBPI21), which is currently in Phase II clinical trials Noun 1. phase II clinical trial - a clinical trial on more persons than in phase I; intended to evaluate the efficacy of a treatment for the condition it is intended to treat; possible side effects are monitored phase II for three different indications. The second patent will provide the company with important protection for its new dimeric BPI protein product, rBPI42. U.S. Patent No. 5,439,807 will issue Aug. 8, 1995, and describes a new method for the recombinant manufacture of BPI and other endotoxin-binding proteins such as lipopolysaccharide-binding protein lipopolysaccharide-binding protein A trace plasma protein that binds to the lipid A moiety of bacterial lipopolysaccharide–LPS or to endotoxin–a glycolipid present in the outer membrane of all gram-negative bacteria (LBP LBP In currencies, this is the abbreviation for the Lebanese Pound. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. ). This method significantly improves production yields. The new product patent will issue Sept. 5, 1995, and describes novel pharmaceutical compositions of BPI dimers, which possess certain enhanced biological properties. XOMA is in preclinical tests with one of these dimers, rBPI42 (XMP (X/Open Management Protocol) A high-level network management protocol governed by X/Open. Network management software written to the XMP interface is shielded from the details of the underlying SNMP or CMIP protocols. 200), for ophthalmic indications. "These two new patents make a substantial contribution to XOMA's expanding BPI-related patent portfolio, which now includes 6 issued U.S. and European patents, 6 additional U.S. notices of allowance and more than 20 additional patent applications pending," said John L. Castello, chairman, president and chief executive officer of XOMA. "The three efficacy trials currently underway with Neuprex, coupled with our increasingly broad patent position, give XOMA a solid foundation for advancing our BPI products toward commercialization." BPI is a naturally-occurring human protein that kills bacteria and neutralizes poisonous endotoxins. BPI-derived products developed by XOMA, such as Neuprex, show additional therapeutic properties. These properties include efficacy in treating fungal infections Fungal infections Several thousand species of fungi have been described, but fewer than 100 are routinely associated with invasive diseases of humans. and in inhibiting angiogenesis angiogenesis /an·gio·gen·e·sis/ (-jen´e-sis) vasculogenesis; development of blood vessels either in the embryo or in the form of neovascularization or revascularization. an·gi·o·gen·e·sis n. and inflammation, as well as enhancing the potency of antibiotics and reversing bacterial resistance. XOMA Corporation is a biopharmaceutical company engaged in the development of products for the treatment of major complications due to infectious diseases infectious diseases: see communicable diseases. , traumatic injury and surgery. The company has placed primary emphasis on the accelerated development of its product, Neuprex, for multiple indications. XOMA is headquartered in Berkeley, Calif. CONTACT: XOMA Corporation Ellen M. Martin, 510/644-1170 or 800/BIO-XOMA |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion